Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study
暂无分享,去创建一个
M. Liedtke | H. Kantarjian | E. Jabbour | W. Stock | D. DeAngelo | S. O'brien | A. Advani | E. Vandendries | Jane Liang White | M. Stelljes | N. Goekbuget | Tao Wang | B. Sleight